Garry A. Nicholson - 12 Jun 2024 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Director
Signature
/s/ Zoran Zdraveski, Attorney-in-Fact
Issuer symbol
TCRX
Transactions as of
12 Jun 2024
Net transactions value
$0
Form type
4
Filing time
14 Jun 2024, 16:20:03 UTC
Previous filing
28 May 2024
Next filing
14 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +47,500 $0.000000 47,500 12 Jun 2024 Voting Common Stock 47,500 $8.88 Direct F1
transaction TCRX Stock Option (Right to Buy) Award $0 +23,750 $0.000000 23,750 12 Jun 2024 Voting Common Stock 23,750 $8.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.
F2 The shares subject to this option shall vest and become exercisable with respect to one-third of the shares on June 12, 2025, with the balance vesting thereafter in 24 equal monthly installments, subject to the Reporting Person's continued service at each such time.